AG˹ٷ

STOCK TITAN

[Form 4] CaliberCos Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Citigroup Global Markets Holdings Inc. (guaranteed by Citigroup Inc.) is offering $250,000 of Autocallable Contingent Coupon Equity-Linked Securities tied to the common stock of Alnylam Pharmaceuticals, Inc. (ALNY). The notes are part of the issuer’s Medium-Term Senior Notes, Series N, and are offered under a 424(b)(2) prospectus supplement.

Economics

  • Denomination: $1,000 per security.
  • Issue price: $1,000; estimated value on the pricing date: $964.60 (reflects distribution/hedging costs and internal funding rate).
  • Underwriting fee: up to $20 (2.0%) per note; net proceeds to issuer: $980.
  • Initial underlying value (ALNY close 30-Jun-2025): $326.09.

Coupon mechanics

  • Quarterly contingent coupon of 3.00% of par (12.00% p.a.) paid only if ALNY’s closing price on the relevant valuation date is � the coupon barrier of $195.654 (60 % of initial value).
  • If the barrier is breached, that coupon period pays $0; missed coupons are not recaptured.

Autocall feature

  • On each valuation date from 30-Sep-2025 to 30-Mar-2028, the notes autocall at par (plus coupon) if ALNY � initial value. Early redemption shortens the maximum coupon horizon.

Principal repayment at maturity (6-Jul-2028)

  • If not previously called and final ALNY price � final barrier of $195.654 (60 % of initial): receive par plus final coupon.
  • If final price < barrier: receive $1,000 × (1 + underlying return), exposing investors to full downside, potentially zero.

Risk profile

  • No principal protection; up to 100 % loss possible.
  • High probability of missed coupons if ALNY stays below the 60 % threshold.
  • Credit exposure to Citigroup Global Markets Holdings Inc. and guarantor Citigroup Inc.
  • No listing; secondary market liquidity depends solely on CGMI.
  • Tax treatment uncertain; issuer intends to treat coupons as ordinary income.

Key dates: Pricing 30-Jun-2025; Issue 3-Jul-2025; first valuation/autocall 30-Sep-2025; maturity 6-Jul-2028.

The product targets investors seeking enhanced income versus conventional Citi debt but who can tolerate equity risk in a single biotech name, potential illiquidity, and complex tax treatment.

Citigroup Global Markets Holdings Inc. (garantita da Citigroup Inc.) offre $250.000 di Obbligazioni Azionarie con Cedola Contingente Autocallable collegate alle azioni ordinarie di Alnylam Pharmaceuticals, Inc. (ALNY). Le note fanno parte delle Medium-Term Senior Notes, Serie N, dell’emittente e sono offerte tramite un supplemento al prospetto 424(b)(2).

Dettagli economici

  • Taglio nominale: $1.000 per titolo.
  • Prezzo di emissione: $1.000; valore stimato alla data di prezzo: $964,60 (include costi di distribuzione/copertura e tasso di finanziamento interno).
  • Commissione di collocamento: fino a $20 (2,0%) per nota; proventi netti per l’emittente: $980.
  • Valore iniziale sottostante (chiusura ALNY 30-giu-2025): $326,09.

Meccanismo della cedola

  • Cedola trimestrale contingente del 3,00% del valore nominale (12,00% annuo), pagata solo se il prezzo di chiusura di ALNY alla data di valutazione è � la barriera cedolare di $195,654 (60% del valore iniziale).
  • Se la barriera non viene raggiunta, la cedola di quel periodo è $0; le cedole non pagate non vengono recuperate.

Caratteristica autocall

  • Ad ogni data di valutazione dal 30-set-2025 al 30-mar-2028, le note vengono rimborsate anticipatamente a valore nominale (più cedola) se ALNY � valore iniziale. Il rimborso anticipato riduce l’orizzonte massimo delle cedole.

Rimborso del capitale a scadenza (6-lug-2028)

  • Se non richiamate prima e prezzo finale ALNY � barriera finale di $195,654 (60% del valore iniziale): ricezione del valore nominale più la cedola finale.
  • Se prezzo finale < barriera: ricezione di $1.000 × (1 + rendimento sottostante), esponendo gli investitori a una perdita totale, potenzialmente fino a zero.

Profilo di rischio

  • Assenza di protezione del capitale; possibile perdita fino al 100%.
  • Alta probabilità di mancato pagamento delle cedole se ALNY resta sotto la soglia del 60%.
  • Rischio di credito verso Citigroup Global Markets Holdings Inc. e garante Citigroup Inc.
  • Non quotato; la liquidità sul mercato secondario dipende esclusivamente da CGMI.
  • Trattamento fiscale incerto; l’emittente intende considerare le cedole come reddito ordinario.

Date chiave: Prezzo 30-giu-2025; Emissione 3-lug-2025; prima valutazione/autocall 30-set-2025; scadenza 6-lug-2028.

Il prodotto è destinato a investitori che cercano un reddito superiore rispetto al debito tradizionale Citi ma che possono tollerare il rischio azionario su un singolo titolo biotech, potenziale illiquidità e complessità fiscale.

Citigroup Global Markets Holdings Inc. (garantizado por Citigroup Inc.) ofrece $250,000 en Valores Vinculados a Acciones con Cupón Contingente Autollamable ligados a las acciones ordinarias de Alnylam Pharmaceuticals, Inc. (ALNY). Los bonos forman parte de las Medium-Term Senior Notes, Serie N, del emisor y se ofrecen bajo un suplemento de prospecto 424(b)(2).

Detalles económicos

  • ٱԴdzԲó: $1,000 por título.
  • Precio de emisión: $1,000; valor estimado en la fecha de precio: $964.60 (incluye costos de distribución/cobertura y tasa interna de financiamiento).
  • Comisión de suscripción: hasta $20 (2.0%) por nota; ingresos netos para el emisor: $980.
  • Valor inicial subyacente (cierre ALNY 30-jun-2025): $326.09.

Mecánica del cupón

  • Cupón trimestral contingente del 3.00% del valor nominal (12.00% anual), pagadero solo si el precio de cierre de ALNY en la fecha de valoración es � la barrera del cupón de $195.654 (60% del valor inicial).
  • Si se incumple la barrera, ese periodo no paga cupón ($0); los cupones no pagados no se recuperan.

Característica autollamada

  • En cada fecha de valoración desde el 30-sep-2025 hasta el 30-mar-2028, las notas se autollaman a la par (más cupón) si ALNY � valor inicial. El reembolso anticipado acorta el horizonte máximo de cupón.

Reembolso del principal al vencimiento (6-jul-2028)

  • Si no se han autollamado y el precio final de ALNY � barrera final de $195.654 (60% del inicial): se recibe el valor nominal más el cupón final.
  • Si el precio final < barrera: se recibe $1,000 × (1 + retorno subyacente), exponiendo a los inversores a la pérdida total, potencialmente cero.

Perfil de riesgo

  • Sin protección del capital; posible pérdida de hasta el 100%.
  • Alta probabilidad de cupones no pagados si ALNY se mantiene por debajo del 60%.
  • Exposición crediticia a Citigroup Global Markets Holdings Inc. y garante Citigroup Inc.
  • No cotizado; la liquidez en el mercado secundario depende exclusivamente de CGMI.
  • Tratamiento fiscal incierto; el emisor pretende tratar los cupones como ingresos ordinarios.

Fechas clave: Precio 30-jun-2025; Emisión 3-jul-2025; primera valoración/autollamada 30-sep-2025; vencimiento 6-jul-2028.

El producto está dirigido a inversores que buscan ingresos mejorados frente a la deuda convencional de Citi, pero que pueden tolerar riesgo accionario en una sola empresa biotecnológica, posible iliquidez y tratamiento fiscal complejo.

Citigroup Global Markets Holdings Inc. (Citigroup Inc. 보증)에서 Alnylam Pharmaceuticals, Inc. (ALNY) 보통주에 연계� 자동상환� 조건부 쿠폰 주식연계증권 25� 달러� 제공합니�. � 채권은 발행자의 중기 선순� 채권 시리� N� 속하� 424(b)(2) 보충설명� 하에 제공됩니�.

경제� 조건

  • 액면가: 증권� $1,000.
  • 발행갶: $1,000; 가� 결정� 추정 가�: $964.60 (배분/헤지 비용 � 내부 자금 조달� 반영).
  • 인수 수수�: 노트� 최대 $20 (2.0%); 발행� 순수�: $980.
  • 초기 기초자산 가� (ALNY 2025� 6� 30� 종가): $326.09.

쿠폰 구조

  • 분기� 조건부 쿠폰 3.00% (� 12.00%)� 해당 평가일에 ALNY 종가가 쿠폰 장벽$195.654 (초기 가치의 60%) 이상� 경우에만 지급됩니다.
  • 장벽 미달 � 해당 기간 쿠폰은 $0이며, 미지� 쿠폰은 회복되지 않습니다.

자동상환 기능

  • 2025� 9� 30일부� 2028� 3� 30일까지 � 평가일에 ALNY가 초기 가� 이상이면 노트� 액면가� 자동상환됩니�(쿠폰 포함). 조기 상환 � 최대 쿠폰 기간� 단축됩니�.

만기 � 원금 상환 (2028� 7� 6�)

  • 조기 상환되지 않고 최종 ALNY 가격이 최종 장벽� $195.654 이상� 경우: 액면가와 최종 쿠폰� 수령합니�.
  • 최종 가격이 장벽 미만� 경우: $1,000 × (1 + 기초자산 수익�)� 수령하며, 투자자는 전액 손실 위험� 노출� � 있습니다.

위험 프로�

  • 원금 보호 없음; 최대 100% 손실 가�.
  • ALNY가 60% 이하� 머물 경우 쿠폰 미지� 가능성 높음.
  • Citigroup Global Markets Holdings Inc. � 보증� Citigroup Inc.� 대� 신용 위험.
  • 상장되지 않음; 2� 시장 유동성은 CGMI� 전적으로 의존.
  • 세금 처리 불확�; 발행자는 쿠폰� 일반 소득으로 처리� 계획.

주요 일정: 가� 결정 2025� 6� 30�; 발행 2025� 7� 3�; � 평가/자동상환 2025� 9� 30�; 만기 2028� 7� 6�.

� 상품은 전통적인 Citi 채권 대� 향상� 수익� 원하� 투자� � 단일 바이오텍 종목� 주식 위험, 잠재� 유동� 부� � 복잡� 세금 처리� 감수� � 있는 투자자를 대상으� 합니�.

Citigroup Global Markets Holdings Inc. (garanti par Citigroup Inc.) propose 250 000 $ de titres liés à des actions avec coupon conditionnel autocallable liés aux actions ordinaires de Alnylam Pharmaceuticals, Inc. (ALNY). Les notes font partie des Medium-Term Senior Notes, série N, de l’émetteur et sont offertes sous un supplément de prospectus 424(b)(2).

Aspects économiques

  • Valeur nominale : 1 000 $ par titre.
  • Prix d’émission : 1 000 $ ; valeur estimée à la date de tarification : 964,60 $ (inclut les coûts de distribution/couverture et le taux de financement interne).
  • Frais de souscription : jusqu’� 20 $ (2,0 %) par note ; produit net pour l’émetteur : 980 $.
  • Valeur initiale sous-jacente (clôture ALNY au 30 juin 2025) : 326,09 $.

Mécanique du coupon

  • Coupon trimestriel conditionnel de 3,00 % du pair (12,00 % par an), versé uniquement si le cours de clôture d’ALNY à la date d’évaluation est � à la barrière du coupon de 195,654 $ (60 % de la valeur initiale).
  • Si la barrière est franchie à la baisse, ce coupon est de 0 $ ; les coupons manqués ne sont pas récupérés.

Caractéristique autocall

  • À chaque date d’évaluation du 30 sept. 2025 au 30 mars 2028, les notes sont remboursées automatiquement au pair (plus coupon) si ALNY � valeur initiale. Le remboursement anticipé réduit l’horizon maximal des coupons.

Remboursement du capital à l’échéance (6 juillet 2028)

  • Si non rappelées auparavant et que le cours final d’ALNY est � à la barrière finale de 195,654 $ (60 % de la valeur initiale) : remboursement au pair plus coupon final.
  • Si le cours final < barrière : remboursement de 1 000 $ × (1 + rendement sous-jacent), exposant les investisseurs à une perte totale, potentiellement jusqu’� zéro.

Profil de risque

  • Pas de protection du capital ; perte possible jusqu’� 100 %.
  • Forte probabilité de coupons manqués si ALNY reste sous le seuil de 60 %.
  • Exposition au risque de crédit de Citigroup Global Markets Holdings Inc. et du garant Citigroup Inc.
  • Non coté ; la liquidité du marché secondaire dépend uniquement de CGMI.
  • Traitement fiscal incertain ; l’émetteur a l’intention de considérer les coupons comme un revenu ordinaire.

Dates clés : tarification 30 juin 2025 ; émission 3 juillet 2025 ; première évaluation/autocall 30 sept. 2025 ; échéance 6 juillet 2028.

Ce produit s’adresse aux investisseurs recherchant un revenu amélioré par rapport à la dette conventionnelle de Citi, mais pouvant tolérer le risque action lié à une seule valeur biotechnologique, une possible illiquidité et une fiscalité complexe.

Citigroup Global Markets Holdings Inc. (garantiert durch Citigroup Inc.) bietet $250.000 an Autocallable Contingent Coupon Equity-Linked Securities an, die an die Stammaktien von Alnylam Pharmaceuticals, Inc. (ALNY) gekoppelt sind. Die Schuldverschreibungen sind Teil der Medium-Term Senior Notes, Serie N, des Emittenten und werden unter einem 424(b)(2) Prospektzusatz angeboten.

Wirtschaftliche Eckdaten

  • Nennwert: $1.000 pro Wertpapier.
  • Ausgabepreis: $1.000; geschätzter Wert zum Pricing-Datum: $964,60 (berücksichtigt Vertriebs-/Hedgingkosten und interne Finanzierungskosten).
  • Underwriting-Gebühr: bis zu $20 (2,0%) pro Note; Nettoerlös für den Emittenten: $980.
  • Anfänglicher Basiswert (ALNY Schlusskurs 30. Juni 2025): $326,09.

Kuponmechanik

  • Quartalsweise bedingter Kupon von 3,00% des Nennwerts (12,00% p.a.), zahlbar nur wenn ALNY-Schlusskurs am jeweiligen Bewertungstag � der Kuponbarriere von $195,654 (60 % des Anfangswerts) ist.
  • Wird die Barriere unterschritten, beträgt der Kupon für diesen Zeitraum $0; nicht gezahlte Kupons verfallen.

Autocall-Funktion

  • An jedem Bewertungstag von 30. Sep. 2025 bis 30. Mär. 2028 erfolgt ein Autocall zum Nennwert (plus Kupon), falls ALNY � Anfangswert. Vorzeitige Rückzahlung verkürzt den maximalen Kuponzeitraum.

Kapitalrückzahlung bei Fälligkeit (6. Juli 2028)

  • Sofern nicht vorher autogekündigt und der finale ALNY-Kurs � Endbarriere von $195,654 (60 % des Anfangswerts) ist: Rückzahlung des Nennwerts plus finalem Kupon.
  • Liegt der Endkurs unter der Barriere: Rückzahlung von $1.000 × (1 + Basisrendite), wodurch Anleger dem vollen Abwärtsrisiko ausgesetzt sind, potenziell bis auf Null.

Risikoprofil

  • Kein Kapitalschutz; Verlust bis zu 100 % möglich.
  • Hohe Wahrscheinlichkeit entgangener Kupons, wenn ALNY unter der 60 %-Schwelle bleibt.
  • Kreditrisiko gegenüber Citigroup Global Markets Holdings Inc. und dem Garanten Citigroup Inc..
  • Keine Börsennotierung; Sekundärmarktliquidität hängt ausschließlich von CGMI ab.
  • Unklare steuerliche Behandlung; Emittent beabsichtigt, die Kupons als gewöhnliches Einkommen zu behandeln.

Wichtige Termine: Preisfestsetzung 30. Juni 2025; Emission 3. Juli 2025; erste Bewertung/Autocall 30. Sep. 2025; Fälligkeit 6. Juli 2028.

Das Produkt richtet sich an Anleger, die im Vergleich zu herkömmlichen Citi-Anleihen ein höheres Einkommen suchen, aber das Aktienrisiko eines einzelnen Biotech-Unternehmens, potenzielle Illiquidität und komplexe steuerliche Behandlung akzeptieren können.

Positive
  • 12 % contingent coupon offers income potential well above Citi’s conventional debt of similar maturity.
  • 60 % downside barrier provides limited cushion versus full ALNY exposure.
  • Citigroup Inc. guarantee backs payments, adding investment-grade credit support.
Negative
  • Full principal loss if ALNY falls more than 40 % at final valuation.
  • Coupons are conditional; any valuation date below barrier cancels that period’s payment.
  • Automatic call can truncate income stream if ALNY recovers, capping upside.
  • Estimated value (96.46 % of par) highlights 3.5 % embedded costs at inception.
  • No exchange listing limits liquidity; secondary bids depend solely on CGMI discretion.
  • Single-stock concentration in a volatile biotech elevates idiosyncratic risk.

Insights

TL;DR High 12 % headline yield, but downside to zero and likely early call make risk-adjusted return modest.

The note’s 12 % contingent coupon looks attractive, yet the 60 % barrier means only moderate downside protection. ALNY is a mid-cap biotech with historical volatility above 40 %, increasing odds of barrier breaches and missed coupons. Because autocall triggers at the initial price, any meaningful rebound in ALNY will redeem the note early, capping income. The estimated value (96.46 % of par) indicates a 3.5 % structuring cost, typical for retail notes. Overall impact on Citi is negligible; for investors the risk/return trade-off is neutral to slightly negative.

TL;DR Concentration in a single volatile biotech plus unsecured Citi credit adds significant tail risk.

Investors face three stacked risks: (1) market � ALNY price swings could eliminate coupons and principal; (2) liquidity � no exchange listing and discretionary CGMI market-making; (3) credit � unsecured claim on Citi Group. The 40 % buffer (100 %-60 %) may seem ample, but biotech drawdowns of 50-60 % are not uncommon. Internal funding rate pricing and bid-ask spreads further erode exit values. From a portfolio perspective, the note is best suited for speculative yield enhancement, not core fixed income.

Citigroup Global Markets Holdings Inc. (garantita da Citigroup Inc.) offre $250.000 di Obbligazioni Azionarie con Cedola Contingente Autocallable collegate alle azioni ordinarie di Alnylam Pharmaceuticals, Inc. (ALNY). Le note fanno parte delle Medium-Term Senior Notes, Serie N, dell’emittente e sono offerte tramite un supplemento al prospetto 424(b)(2).

Dettagli economici

  • Taglio nominale: $1.000 per titolo.
  • Prezzo di emissione: $1.000; valore stimato alla data di prezzo: $964,60 (include costi di distribuzione/copertura e tasso di finanziamento interno).
  • Commissione di collocamento: fino a $20 (2,0%) per nota; proventi netti per l’emittente: $980.
  • Valore iniziale sottostante (chiusura ALNY 30-giu-2025): $326,09.

Meccanismo della cedola

  • Cedola trimestrale contingente del 3,00% del valore nominale (12,00% annuo), pagata solo se il prezzo di chiusura di ALNY alla data di valutazione è � la barriera cedolare di $195,654 (60% del valore iniziale).
  • Se la barriera non viene raggiunta, la cedola di quel periodo è $0; le cedole non pagate non vengono recuperate.

Caratteristica autocall

  • Ad ogni data di valutazione dal 30-set-2025 al 30-mar-2028, le note vengono rimborsate anticipatamente a valore nominale (più cedola) se ALNY � valore iniziale. Il rimborso anticipato riduce l’orizzonte massimo delle cedole.

Rimborso del capitale a scadenza (6-lug-2028)

  • Se non richiamate prima e prezzo finale ALNY � barriera finale di $195,654 (60% del valore iniziale): ricezione del valore nominale più la cedola finale.
  • Se prezzo finale < barriera: ricezione di $1.000 × (1 + rendimento sottostante), esponendo gli investitori a una perdita totale, potenzialmente fino a zero.

Profilo di rischio

  • Assenza di protezione del capitale; possibile perdita fino al 100%.
  • Alta probabilità di mancato pagamento delle cedole se ALNY resta sotto la soglia del 60%.
  • Rischio di credito verso Citigroup Global Markets Holdings Inc. e garante Citigroup Inc.
  • Non quotato; la liquidità sul mercato secondario dipende esclusivamente da CGMI.
  • Trattamento fiscale incerto; l’emittente intende considerare le cedole come reddito ordinario.

Date chiave: Prezzo 30-giu-2025; Emissione 3-lug-2025; prima valutazione/autocall 30-set-2025; scadenza 6-lug-2028.

Il prodotto è destinato a investitori che cercano un reddito superiore rispetto al debito tradizionale Citi ma che possono tollerare il rischio azionario su un singolo titolo biotech, potenziale illiquidità e complessità fiscale.

Citigroup Global Markets Holdings Inc. (garantizado por Citigroup Inc.) ofrece $250,000 en Valores Vinculados a Acciones con Cupón Contingente Autollamable ligados a las acciones ordinarias de Alnylam Pharmaceuticals, Inc. (ALNY). Los bonos forman parte de las Medium-Term Senior Notes, Serie N, del emisor y se ofrecen bajo un suplemento de prospecto 424(b)(2).

Detalles económicos

  • ٱԴdzԲó: $1,000 por título.
  • Precio de emisión: $1,000; valor estimado en la fecha de precio: $964.60 (incluye costos de distribución/cobertura y tasa interna de financiamiento).
  • Comisión de suscripción: hasta $20 (2.0%) por nota; ingresos netos para el emisor: $980.
  • Valor inicial subyacente (cierre ALNY 30-jun-2025): $326.09.

Mecánica del cupón

  • Cupón trimestral contingente del 3.00% del valor nominal (12.00% anual), pagadero solo si el precio de cierre de ALNY en la fecha de valoración es � la barrera del cupón de $195.654 (60% del valor inicial).
  • Si se incumple la barrera, ese periodo no paga cupón ($0); los cupones no pagados no se recuperan.

Característica autollamada

  • En cada fecha de valoración desde el 30-sep-2025 hasta el 30-mar-2028, las notas se autollaman a la par (más cupón) si ALNY � valor inicial. El reembolso anticipado acorta el horizonte máximo de cupón.

Reembolso del principal al vencimiento (6-jul-2028)

  • Si no se han autollamado y el precio final de ALNY � barrera final de $195.654 (60% del inicial): se recibe el valor nominal más el cupón final.
  • Si el precio final < barrera: se recibe $1,000 × (1 + retorno subyacente), exponiendo a los inversores a la pérdida total, potencialmente cero.

Perfil de riesgo

  • Sin protección del capital; posible pérdida de hasta el 100%.
  • Alta probabilidad de cupones no pagados si ALNY se mantiene por debajo del 60%.
  • Exposición crediticia a Citigroup Global Markets Holdings Inc. y garante Citigroup Inc.
  • No cotizado; la liquidez en el mercado secundario depende exclusivamente de CGMI.
  • Tratamiento fiscal incierto; el emisor pretende tratar los cupones como ingresos ordinarios.

Fechas clave: Precio 30-jun-2025; Emisión 3-jul-2025; primera valoración/autollamada 30-sep-2025; vencimiento 6-jul-2028.

El producto está dirigido a inversores que buscan ingresos mejorados frente a la deuda convencional de Citi, pero que pueden tolerar riesgo accionario en una sola empresa biotecnológica, posible iliquidez y tratamiento fiscal complejo.

Citigroup Global Markets Holdings Inc. (Citigroup Inc. 보증)에서 Alnylam Pharmaceuticals, Inc. (ALNY) 보통주에 연계� 자동상환� 조건부 쿠폰 주식연계증권 25� 달러� 제공합니�. � 채권은 발행자의 중기 선순� 채권 시리� N� 속하� 424(b)(2) 보충설명� 하에 제공됩니�.

경제� 조건

  • 액면가: 증권� $1,000.
  • 발행갶: $1,000; 가� 결정� 추정 가�: $964.60 (배분/헤지 비용 � 내부 자금 조달� 반영).
  • 인수 수수�: 노트� 최대 $20 (2.0%); 발행� 순수�: $980.
  • 초기 기초자산 가� (ALNY 2025� 6� 30� 종가): $326.09.

쿠폰 구조

  • 분기� 조건부 쿠폰 3.00% (� 12.00%)� 해당 평가일에 ALNY 종가가 쿠폰 장벽$195.654 (초기 가치의 60%) 이상� 경우에만 지급됩니다.
  • 장벽 미달 � 해당 기간 쿠폰은 $0이며, 미지� 쿠폰은 회복되지 않습니다.

자동상환 기능

  • 2025� 9� 30일부� 2028� 3� 30일까지 � 평가일에 ALNY가 초기 가� 이상이면 노트� 액면가� 자동상환됩니�(쿠폰 포함). 조기 상환 � 최대 쿠폰 기간� 단축됩니�.

만기 � 원금 상환 (2028� 7� 6�)

  • 조기 상환되지 않고 최종 ALNY 가격이 최종 장벽� $195.654 이상� 경우: 액면가와 최종 쿠폰� 수령합니�.
  • 최종 가격이 장벽 미만� 경우: $1,000 × (1 + 기초자산 수익�)� 수령하며, 투자자는 전액 손실 위험� 노출� � 있습니다.

위험 프로�

  • 원금 보호 없음; 최대 100% 손실 가�.
  • ALNY가 60% 이하� 머물 경우 쿠폰 미지� 가능성 높음.
  • Citigroup Global Markets Holdings Inc. � 보증� Citigroup Inc.� 대� 신용 위험.
  • 상장되지 않음; 2� 시장 유동성은 CGMI� 전적으로 의존.
  • 세금 처리 불확�; 발행자는 쿠폰� 일반 소득으로 처리� 계획.

주요 일정: 가� 결정 2025� 6� 30�; 발행 2025� 7� 3�; � 평가/자동상환 2025� 9� 30�; 만기 2028� 7� 6�.

� 상품은 전통적인 Citi 채권 대� 향상� 수익� 원하� 투자� � 단일 바이오텍 종목� 주식 위험, 잠재� 유동� 부� � 복잡� 세금 처리� 감수� � 있는 투자자를 대상으� 합니�.

Citigroup Global Markets Holdings Inc. (garanti par Citigroup Inc.) propose 250 000 $ de titres liés à des actions avec coupon conditionnel autocallable liés aux actions ordinaires de Alnylam Pharmaceuticals, Inc. (ALNY). Les notes font partie des Medium-Term Senior Notes, série N, de l’émetteur et sont offertes sous un supplément de prospectus 424(b)(2).

Aspects économiques

  • Valeur nominale : 1 000 $ par titre.
  • Prix d’émission : 1 000 $ ; valeur estimée à la date de tarification : 964,60 $ (inclut les coûts de distribution/couverture et le taux de financement interne).
  • Frais de souscription : jusqu’� 20 $ (2,0 %) par note ; produit net pour l’émetteur : 980 $.
  • Valeur initiale sous-jacente (clôture ALNY au 30 juin 2025) : 326,09 $.

Mécanique du coupon

  • Coupon trimestriel conditionnel de 3,00 % du pair (12,00 % par an), versé uniquement si le cours de clôture d’ALNY à la date d’évaluation est � à la barrière du coupon de 195,654 $ (60 % de la valeur initiale).
  • Si la barrière est franchie à la baisse, ce coupon est de 0 $ ; les coupons manqués ne sont pas récupérés.

Caractéristique autocall

  • À chaque date d’évaluation du 30 sept. 2025 au 30 mars 2028, les notes sont remboursées automatiquement au pair (plus coupon) si ALNY � valeur initiale. Le remboursement anticipé réduit l’horizon maximal des coupons.

Remboursement du capital à l’échéance (6 juillet 2028)

  • Si non rappelées auparavant et que le cours final d’ALNY est � à la barrière finale de 195,654 $ (60 % de la valeur initiale) : remboursement au pair plus coupon final.
  • Si le cours final < barrière : remboursement de 1 000 $ × (1 + rendement sous-jacent), exposant les investisseurs à une perte totale, potentiellement jusqu’� zéro.

Profil de risque

  • Pas de protection du capital ; perte possible jusqu’� 100 %.
  • Forte probabilité de coupons manqués si ALNY reste sous le seuil de 60 %.
  • Exposition au risque de crédit de Citigroup Global Markets Holdings Inc. et du garant Citigroup Inc.
  • Non coté ; la liquidité du marché secondaire dépend uniquement de CGMI.
  • Traitement fiscal incertain ; l’émetteur a l’intention de considérer les coupons comme un revenu ordinaire.

Dates clés : tarification 30 juin 2025 ; émission 3 juillet 2025 ; première évaluation/autocall 30 sept. 2025 ; échéance 6 juillet 2028.

Ce produit s’adresse aux investisseurs recherchant un revenu amélioré par rapport à la dette conventionnelle de Citi, mais pouvant tolérer le risque action lié à une seule valeur biotechnologique, une possible illiquidité et une fiscalité complexe.

Citigroup Global Markets Holdings Inc. (garantiert durch Citigroup Inc.) bietet $250.000 an Autocallable Contingent Coupon Equity-Linked Securities an, die an die Stammaktien von Alnylam Pharmaceuticals, Inc. (ALNY) gekoppelt sind. Die Schuldverschreibungen sind Teil der Medium-Term Senior Notes, Serie N, des Emittenten und werden unter einem 424(b)(2) Prospektzusatz angeboten.

Wirtschaftliche Eckdaten

  • Nennwert: $1.000 pro Wertpapier.
  • Ausgabepreis: $1.000; geschätzter Wert zum Pricing-Datum: $964,60 (berücksichtigt Vertriebs-/Hedgingkosten und interne Finanzierungskosten).
  • Underwriting-Gebühr: bis zu $20 (2,0%) pro Note; Nettoerlös für den Emittenten: $980.
  • Anfänglicher Basiswert (ALNY Schlusskurs 30. Juni 2025): $326,09.

Kuponmechanik

  • Quartalsweise bedingter Kupon von 3,00% des Nennwerts (12,00% p.a.), zahlbar nur wenn ALNY-Schlusskurs am jeweiligen Bewertungstag � der Kuponbarriere von $195,654 (60 % des Anfangswerts) ist.
  • Wird die Barriere unterschritten, beträgt der Kupon für diesen Zeitraum $0; nicht gezahlte Kupons verfallen.

Autocall-Funktion

  • An jedem Bewertungstag von 30. Sep. 2025 bis 30. Mär. 2028 erfolgt ein Autocall zum Nennwert (plus Kupon), falls ALNY � Anfangswert. Vorzeitige Rückzahlung verkürzt den maximalen Kuponzeitraum.

Kapitalrückzahlung bei Fälligkeit (6. Juli 2028)

  • Sofern nicht vorher autogekündigt und der finale ALNY-Kurs � Endbarriere von $195,654 (60 % des Anfangswerts) ist: Rückzahlung des Nennwerts plus finalem Kupon.
  • Liegt der Endkurs unter der Barriere: Rückzahlung von $1.000 × (1 + Basisrendite), wodurch Anleger dem vollen Abwärtsrisiko ausgesetzt sind, potenziell bis auf Null.

Risikoprofil

  • Kein Kapitalschutz; Verlust bis zu 100 % möglich.
  • Hohe Wahrscheinlichkeit entgangener Kupons, wenn ALNY unter der 60 %-Schwelle bleibt.
  • Kreditrisiko gegenüber Citigroup Global Markets Holdings Inc. und dem Garanten Citigroup Inc..
  • Keine Börsennotierung; Sekundärmarktliquidität hängt ausschließlich von CGMI ab.
  • Unklare steuerliche Behandlung; Emittent beabsichtigt, die Kupons als gewöhnliches Einkommen zu behandeln.

Wichtige Termine: Preisfestsetzung 30. Juni 2025; Emission 3. Juli 2025; erste Bewertung/Autocall 30. Sep. 2025; Fälligkeit 6. Juli 2028.

Das Produkt richtet sich an Anleger, die im Vergleich zu herkömmlichen Citi-Anleihen ein höheres Einkommen suchen, aber das Aktienrisiko eines einzelnen Biotech-Unternehmens, potenzielle Illiquidität und komplexe steuerliche Behandlung akzeptieren können.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
GERBER WILLIAM J

(Last) (First) (Middle)
8901 E MOUNTAIN VIEW RD
#150

(Street)
SCOTTSDALE AZ 85258

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CaliberCos Inc. [ CWD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/17/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Options (right to buy)(1) $3.55 06/17/2025 A 5,052 06/17/2025 06/17/2035 Class A Common Stock 5,052 (2) 15,567 D
Explanation of Responses:
1. Employee Stock Options (right to buy)("Options") granted pursuant to Issuer's 2024 Equity Incentive Plan. Such Options represent a portion of Reporting Person's compensation as a director of Issuer.
2. Not applicable.
Remarks:
/s/ William Gerber 06/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What is the coupon rate on Citigroup7s ALNY-linked notes?

The notes pay a 3.00 % quarterly contingent coupon, equivalent to 12.00 % per annum, when ALNY closes at or above $195.654 on the valuation date.

How does the automatic early redemption work?

On each scheduled valuation date starting 30-Sep-2025, if ALNY 3E= the initial $326.09, the notes are called at $1,000 plus the due coupon.

What happens at maturity if ALNY falls below the 60 % barrier?

Holders receive $1,000 × (1 + underlying return); a 70 % drop would return $300, while a 100 % drop would return $0.

Is the principal protected by FDIC insurance?

No. The securities are unsecured obligations of Citigroup Global Markets Holdings Inc., guaranteed by Citigroup Inc., and are not FDIC-insured.

Why is the estimated value ($964.60) lower than the issue price?

It reflects underwriting fees, hedging costs and the issuer7s internal funding rate; these embedded costs reduce the economic value to investors.

Will the notes trade on an exchange?

No. No listing is planned; any secondary liquidity will be provided, if at all, by CGMI on a discretionary basis.
CaliberCos

NASDAQ:CWD

CWD Rankings

CWD Latest News

CWD Latest SEC Filings

CWD Stock Data

3.63M
683.65k
28.57%
4.6%
0.09%
Asset Management
AG˹ٷ Estate
United States
SCOTTSDALE